⏱ 1 min read
Background
Immitra Bio is a biotech based in Plan-les-Ouates, in the canton of Geneva. It develops in-vivo gene editing therapies designed as off-the-shelf treatments.
The key points
Immitra Bio has closed an upsized pre-seed financing round of 2.4 million francs. The round was led by Backbone Ventures and co-led by OCCIDENT, according to GGBa.
The platform combines a mutation-agnostic gene editing technology with a digital target identification tool. The approach aims to avoid ex-vivo cell manipulation and stem cell transplantation. It should make it possible to treat all patients with a disease, regardless of their mutation.
Key figures
- 2.4 million francs raised in total.
- 2.25 million from venture capital and private investors.
- 150,000 francs secured through non-dilutive funding.
What it means for businesses
The round also includes Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT and the ETH Foundation. Private investors are also taking part.
What's next
The funds will primarily support preclinical proof-of-concept studies for IB-003. This lead candidate targets an inherited anaemia, as a potential one-time curative treatment. The financing will also cover the discovery of new targets and refinement of the platform.
